Search

everythinglearnresearchcommunity

for

Search:↓

E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Vertex pattern hair loss linked to higher prostate cancer risk.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.

Higher BMI and lower testosterone are linked to more aggressive prostate cancer.

Large prostate links to more hair loss, but age of onset doesn't affect it.

Finasteride does not prevent bladder cancer.

The activity of a specific rat enzyme in the prostate and epididymis is highly dependent on the acidity level.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

Short telomeres contribute to aging and cancer, and while telomerase can delay aging, it may also promote cancer.

Lecithin-encapsulated resveratrol nanoparticles could be a safe and effective anti-cancer treatment.

Androgen receptors are key for development and health, affecting conditions like prostate cancer and male pattern baldness.

11α-Hydroxyprogesterone is changed into different substances by certain enzymes and may play a role in prostate cancer.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Early onset baldness in men may indicate a condition similar to PCOS, linked to heart disease, diabetes, and prostate issues.

High levels of ST14 and TMEFF1 proteins in ovarian cancer are linked to worse patient outcomes and may be a new treatment target.

Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.

Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.

Normal levels of DHT can reduce belly fat and increase muscle, but too much can lead to hair loss, prostate issues, and possibly heart disease.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Researchers found 63 genes linked to male-pattern baldness, which could help in understanding its biology and developing new treatments.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

The new particle system could be a promising treatment for diseases related to the 5-α reductase enzyme.